The hits just keep coming for Johnson & Johnson, and now its Type 2 diabetes drug, Invokana, is in the spotlight, again. Invokana, Invokamet, Farxiga, and Xigduo are in a newer class of diabetes drugs called “sodium-glucose co-transporter 2 (SGLT2) inhibitors”. These drugs are designed to lower blood sugar in people with Type 2 Diabetes […]